Author

P. T. Gunning

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Bock· 2 shared R. Moriggl· 2 shared A. Bergthaler· 1 shared A. Boersma· 1 shared A. Lercher· 1 shared A. Orlova· 1 shared A. Pichler· 1 shared A. Popa· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Bock

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 21, 2022

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Suske, H. Sorger, F. Ruge…·R. Moriggl

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

DOI 10.1101/2022.12.21.519945

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivApr 12, 2018

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa…·A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

DOI 10.1016/j.ccell.2018.11.018

proteomicsDNA methylation

𝕏 PostBluesky